z-logo
open-access-imgOpen Access
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032
Author(s) -
Giles Robinson,
Brent A. Orr,
Gang Wu,
Sridharan Gururangan,
Tong Lin,
Ibrahim Qaddoumi,
Roger J. Packer,
Stewart Goldman,
Michael D. Prados,
Annick Desjardins,
Murali Chintagumpala,
Naoko Takebe,
Sue C. Kaste,
Michael Rusch,
Sariah J. Allen,
Arzu OnarThomas,
Clinton F. Stewart,
Maryam Fouladi,
James M. Boyett,
Richard J. Gilbertson,
Tom Curran,
David W. Ellison,
Amar Gajjar
Publication year - 2015
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2014.60.1591
Subject(s) - vismodegib , sonic hedgehog , medulloblastoma , smoothened , medicine , ptch1 , oncology , hedgehog signaling pathway , cancer research , biology , genetics , gene , basal cell carcinoma , basal cell
Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom